Ryan Ramsey Hosn

Ryan Ramsey Hosn

Auto-generated profile, based on publicly available information

Ryan Ramsey Hosn

Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2023 in Chemical Engineering Journal
Verified
Journal Article
Open access
IPIvan S. Pires
Ivan S. Pires
KNKaiyuan Ni
Kaiyuan Ni
MMMariane Bandeira Melo
Mariane Bandeira Melo
NLNa Li
Na Li
EBElana Ben-Akiva
Elana Ben-Akiva
DIDarrell J. Irvine
Darrell J. Irvine
Immune stimulating complexes (ISCOMs) are safe and effective saponin-based adjuvants formed by the self-assembly of saponin, cholesterol, and phospholipids in water to form cage-like 30–40 nm diameter particles. Inclusion of the Toll-like receptor 4 agonist monophosphoryl lipid A (MPLA) in ISCOM particles yields a promising next-generation adjuvant termed Saponin-MPLA NanoParticles (SMNP). In this work, we detail protocols to produce ISCOMs or SMNP via a tangential flow filtration (TFF) process suitable for scalable synthesis and Good Manufacturing Practice (GMP) production of clinical-grade adjuvants. SMNP or ISCOM components were solubilized in micelles of the surfactant MEGA-10, then diluted below the critical micelle concentration (CMC) of the surfactant to drive ISCOM self-assembly. Assembly of ISCOM/SMNP particles using the purified saponin QS-21 used in clinical-grade saponin adjuvants was found to require controlled stepwise dilution of the initial micellar solution, to prevent formation of undesirable kinetically-trapped aggregate species. An optimized protocol gave yields of ~77% based on the initial feed of QS-21 and the final SMNP particle composition mirrored the feed ratios of the components. Further, samples were highly homogeneous with comparable quality to that of material prepared at lab scale by dialysis and purified via size-exclusion chromatography. This protocol may be useful for clinical preparation of ISCOM-based vaccine adjuvants and therapeutics.

2 March 2026 in Nature Biomedical Engineering
Verified
Journal Article
Open access
SFSasan Jalili Firoozinezhad
Sasan Jalili Firoozinezhad
RHRyan R. Hosn
Ryan R. Hosn
WKWei-Che Ko
Wei-Che Ko
KAKhashayar Afshari
Khashayar Afshari
ADAshok Kumar Dhinakaran
Ashok Kumar Dhinakaran
DIDarrell J. Irvine
Darrell J. Irvine
Detecting antigen-specific lymphocytes is crucial for immune monitoring in vaccination, infection, cancer and autoimmunity. However, their low frequency and dispersed distribution make reliable detection challenging. We developed a strategy exploiting the functions of tissue-resident memory T cells (T RM s) to locally concentrate target circulating immune cells in the skin, enabling their non-invasive sampling using a microneedle (MN) skin patch. T RM s were first induced by antigen sensitization and subsequently restimulated by intradermal inoculation of the same antigen to trigger the ‘alarm’ and immune recruitment functions of these cells, leading to accumulation of antigen-specific T cells from the circulation over several days. In mouse vaccination models, MN patches with optimized hydrogel coatings effectively isolated thousands of live antigen-specific lymphocytes and innate immune cells. In a human participant with allergic contact dermatitis, allergen-induced T RM stimulation followed by MN application recovered diverse lymphocyte populations absent from untreated skin sites. These results establish T RM restimulation coupled with MN sampling as a non-invasive platform to monitor both local and systemic antigen-specific immune responses across disease or vaccination settings.

21 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RHRyan Ramsey Hosn
Ryan Ramsey Hosn
OMOriana Marrone Mantovani
Oriana Marrone Mantovani
AMArtemis Margaronis
Artemis Margaronis
JWJames S. Wang
James S. Wang
EKEthan Kriss
Ethan Kriss
SCSantiago Correa
Santiago Correa
Tertiary lymphoid structures (TLSs) are organized three-dimensional immune niches associated with improved antitumor immunity, which has galvanized efforts to induce them artificially using biomaterials. However, these strategies have largely focused on soluble cue delivery, leaving the role of scaffold physical properties poorly understood. Here, we developed injectable, liposome-crosslinked supramolecular hydrogels spanning soft and stiff formulations to determine how scaffold mechanical properties regulate in situ tertiary lymphoid neogenesis. The formulations differed in their viscoelastic properties while maintaining broadly comparable release of ovalbumin and LIGHT. Soft hydrogels underwent distributed cellular infiltration and material replacement, transitioning from an early myeloid-rich response to vascularized, lymphoid-dominant tissues containing B-cell-rich aggregates adjacent to T-cell regions, with B-cell organization peaking at day 14. Single-cell RNA sequencing revealed that transient interferon-associated neutrophil and macrophage states in the early niche preceded the emergence of TLS-associated transcriptional programs across lymphoid and myeloid populations. In contrast, stiff hydrogels resisted infiltration and perpetuated a niche dominated by activated myeloid cells with limited lymphoid organization. Prophylactically implanted soft hydrogels improved early melanoma control relative to stiff hydrogels under checkpoint blockade, and a single soft-hydrogel implantation restrained tumor growth even without checkpoint blockade. Together, these findings establish scaffold mechanics and remodeling as active regulators of engineered immune-tissue organization and provide design principles for directing the development of local TLS-like niches.